retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

A structured, evidence-based regimen that supports each stage of the migraine cycle promotes greater neurological resilience

October 2023: JAMA Research Letter Warns of Possible Ozempic Risks A research letter filed in the Journal of the American Medical Association alleges the risk of adverse gastrointestinal events associated with the use of GLP-1 agonists that are used not only to treat diabetes but also off-label for weight loss

2022;14:e21536

National Bureau of Economic Research Technical Working Paper Series

With an interdisciplinary focus, practitioners utilize ophthalmic imaging, neuroimaging, laboratory evaluation, electrophysiology, pathologic evaluation, and genetic testing to evaluate patients

The distinct contributions of each receptor system - GLP-1-mediated improvements in insulin sensitivity and appetite regulation, GIP-mediated enhancement of insulin secretion and adipose tissue function, and glucagon-mediated direct hepatic metabolic modulation and increased energy expenditure - create synergistic benefits when engaged through dual or triple agonist formulations